FI3541784T3 - Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina - Google Patents
Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina Download PDFInfo
- Publication number
- FI3541784T3 FI3541784T3 FIEP17807779.8T FI17807779T FI3541784T3 FI 3541784 T3 FI3541784 T3 FI 3541784T3 FI 17807779 T FI17807779 T FI 17807779T FI 3541784 T3 FI3541784 T3 FI 3541784T3
- Authority
- FI
- Finland
- Prior art keywords
- azetidine
- salt
- difluorophenoxy
- compound
- formula
- Prior art date
Links
- 150000001539 azetidines Chemical class 0.000 title 1
- 230000000768 catecholaminergic effect Effects 0.000 title 1
- 230000001054 cortical effect Effects 0.000 title 1
- 230000005062 synaptic transmission Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- VXXACJCOSVCADM-UHFFFAOYSA-N 3-(3,5-difluorophenoxy)azetidine Chemical compound FC1=CC(F)=CC(OC2CNC2)=C1 VXXACJCOSVCADM-UHFFFAOYSA-N 0.000 claims 4
- TXTVXNRODZFMEX-UHFFFAOYSA-N 3-(2,3-difluorophenoxy)azetidine Chemical compound FC1=CC=CC(OC2CNC2)=C1F TXTVXNRODZFMEX-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- UGLPJXJCBSHGRH-UHFFFAOYSA-N 3-(2,3,5,6-tetrafluorophenoxy)azetidine Chemical compound FC1=C(OC2CNC2)C(=C(C=C1F)F)F UGLPJXJCBSHGRH-UHFFFAOYSA-N 0.000 claims 2
- UTNJOKZHZHVICP-UHFFFAOYSA-N 3-(2,4-difluorophenoxy)azetidine Chemical compound FC1=CC(F)=CC=C1OC1CNC1 UTNJOKZHZHVICP-UHFFFAOYSA-N 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- YYAJEDYMILIECQ-UHFFFAOYSA-N 3-(2,3,4,5,6-pentafluorophenoxy)azetidine Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1OC1CNC1 YYAJEDYMILIECQ-UHFFFAOYSA-N 0.000 claims 1
- PIMRYTXJZVROJO-UHFFFAOYSA-N 3-(2,3,4-trifluorophenoxy)azetidine Chemical compound FC1=C(F)C(F)=CC=C1OC1CNC1 PIMRYTXJZVROJO-UHFFFAOYSA-N 0.000 claims 1
- QSZKBJBRWVQHHH-UHFFFAOYSA-N 3-(2,4,5-trifluorophenoxy)azetidine Chemical compound FC1=C(OC2CNC2)C=C(C(=C1)F)F QSZKBJBRWVQHHH-UHFFFAOYSA-N 0.000 claims 1
- XXTYTFVOMHMMJV-UHFFFAOYSA-N 3-(2,4,6-trifluorophenoxy)azetidine Chemical compound FC1=C(OC2CNC2)C(=CC(=C1)F)F XXTYTFVOMHMMJV-UHFFFAOYSA-N 0.000 claims 1
- XECNNPZISUHUNI-UHFFFAOYSA-N 3-(2,5-difluorophenoxy)azetidine Chemical compound FC1=CC=C(F)C(OC2CNC2)=C1 XECNNPZISUHUNI-UHFFFAOYSA-N 0.000 claims 1
- NNFXZJSCCQBCFR-UHFFFAOYSA-N 3-(2,6-difluorophenoxy)azetidine Chemical compound FC1=CC=CC(F)=C1OC1CNC1 NNFXZJSCCQBCFR-UHFFFAOYSA-N 0.000 claims 1
- UWJAEZJEHAUARH-UHFFFAOYSA-N 3-(2,6-difluorophenoxy)azetidine hydrochloride Chemical compound Cl.Fc1cccc(F)c1OC1CNC1 UWJAEZJEHAUARH-UHFFFAOYSA-N 0.000 claims 1
- APPWDWVMENBZFH-UHFFFAOYSA-N 3-(3,4-difluorophenoxy)azetidine Chemical compound C1=C(F)C(F)=CC=C1OC1CNC1 APPWDWVMENBZFH-UHFFFAOYSA-N 0.000 claims 1
- LGYZUROTBPYFOS-UHFFFAOYSA-N 3-(3,4-difluorophenoxy)azetidine;hydrochloride Chemical compound Cl.C1=C(F)C(F)=CC=C1OC1CNC1 LGYZUROTBPYFOS-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- -1 azetidine hydrochloric acid salt Chemical class 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16199545 | 2016-11-18 | ||
| PCT/EP2017/079666 WO2018091687A1 (en) | 2016-11-18 | 2017-11-17 | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3541784T3 true FI3541784T3 (fi) | 2023-10-02 |
Family
ID=57348567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17807779.8T FI3541784T3 (fi) | 2016-11-18 | 2017-11-17 | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10875829B1 (enExample) |
| EP (1) | EP3541784B1 (enExample) |
| JP (1) | JP6990702B2 (enExample) |
| CN (1) | CN109963834B (enExample) |
| DK (1) | DK3541784T5 (enExample) |
| ES (1) | ES2962865T3 (enExample) |
| FI (1) | FI3541784T3 (enExample) |
| PL (1) | PL3541784T3 (enExample) |
| PT (1) | PT3541784T (enExample) |
| WO (1) | WO2018091687A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112198237B (zh) * | 2020-05-28 | 2021-08-06 | 扬子江药业集团广州海瑞药业有限公司 | 一种盐酸奈康唑杂质检测控制分析方法 |
| EP4739654A1 (en) | 2023-07-06 | 2026-05-13 | Integrative Research Laboratories Sweden AB | Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof |
| WO2025008506A1 (en) | 2023-07-06 | 2025-01-09 | Integrative Research Laboratories Sweden Ab | 3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638939A2 (en) * | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| EP2367785B1 (en) | 2008-11-24 | 2014-10-15 | Integrative Research Laboratories Sweden AB | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| JP5716202B2 (ja) | 2008-11-24 | 2015-05-13 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体 |
| JP2012515760A (ja) | 2009-01-20 | 2012-07-12 | ファイザー・インク | 置換ピラジノンアミド |
| TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| JP2013519732A (ja) * | 2010-02-17 | 2013-05-30 | アムジエン・インコーポレーテツド | 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体 |
| EP2718295A1 (en) | 2011-06-07 | 2014-04-16 | Pfizer Inc | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| CN104093720B (zh) * | 2012-01-26 | 2017-04-12 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
| KR101894681B1 (ko) * | 2014-08-27 | 2018-09-04 | 에프. 호프만-라 로슈 아게 | Taar 리간드로서의 치환된 아제티딘 유도체 |
| US10040759B2 (en) * | 2014-11-05 | 2018-08-07 | Dart Neuroscience (Cayman) Ltd. | Substituted azetidinyl compounds as GlyT1 inhibitors |
| EP3297987B1 (en) * | 2015-05-20 | 2019-05-15 | Integrative Research Laboratories Sweden AB | Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission |
| CN108026030B (zh) | 2015-09-18 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 一种氘代化合物的制备方法 |
| TWI752098B (zh) * | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
-
2017
- 2017-11-17 ES ES17807779T patent/ES2962865T3/es active Active
- 2017-11-17 FI FIEP17807779.8T patent/FI3541784T3/fi active
- 2017-11-17 PL PL17807779.8T patent/PL3541784T3/pl unknown
- 2017-11-17 US US16/461,086 patent/US10875829B1/en active Active
- 2017-11-17 EP EP17807779.8A patent/EP3541784B1/en active Active
- 2017-11-17 DK DK17807779.8T patent/DK3541784T5/da active
- 2017-11-17 JP JP2019525851A patent/JP6990702B2/ja active Active
- 2017-11-17 CN CN201780069687.6A patent/CN109963834B/zh active Active
- 2017-11-17 PT PT178077798T patent/PT3541784T/pt unknown
- 2017-11-17 WO PCT/EP2017/079666 patent/WO2018091687A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019535715A (ja) | 2019-12-12 |
| CN109963834B (zh) | 2023-04-14 |
| US10875829B1 (en) | 2020-12-29 |
| CN109963834A (zh) | 2019-07-02 |
| PL3541784T3 (pl) | 2024-03-11 |
| ES2962865T3 (es) | 2024-03-21 |
| WO2018091687A1 (en) | 2018-05-24 |
| PT3541784T (pt) | 2023-11-22 |
| EP3541784A1 (en) | 2019-09-25 |
| DK3541784T3 (en) | 2023-10-23 |
| DK3541784T5 (da) | 2024-09-16 |
| EP3541784B1 (en) | 2023-09-13 |
| JP6990702B2 (ja) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA109459C2 (xx) | ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE) | |
| PH12017502351A1 (en) | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor | |
| EA201291435A1 (ru) | Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace) | |
| MX2015011618A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso. | |
| EA201291366A1 (ru) | Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace) | |
| MY195742A (en) | Isoindoline-1-One Derivatives as Cholinergic Muscarinic M1 Receptor Positive Alloesteric Modulator Activity for the Treatment of Alzheimers Disease | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| TN2013000285A1 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
| PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| MX366855B (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| GEAP202014908A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| UA109800C2 (xx) | ПОХІДНІ 6,7-ДИГІДРОПІРАЗОЛО$1,5-a]ПІРАЗИН-4-ІЛАМІНУ, КОРИСНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE) | |
| CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
| BR112017022568A2 (pt) | compostos e seus usos como inibidores de bace1 | |
| UY34239A (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| MX2019007104A (es) | Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso. | |
| MX2017008083A (es) | Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa. | |
| MX2019007100A (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. | |
| MX2019007101A (es) | Derivados de oxazina como inhibidores de beta secretasa y metodos de uso. | |
| MD20160109A2 (ro) | Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 | |
| NO20090402L (no) | Glysintransportor-1-inhibitorer | |
| MX2019007102A (es) | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. | |
| GT200700097A (es) | Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| MX2019007103A (es) | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. | |
| BR112018005591A2 (pt) | derivados 2,3,4,5-tetra-hidropiridin-6-amina |